Granzyme B Contributes to Barrier Dysfunction in Oxazolone-Induced Skin Inflammation through E-Cadherin and FLG Cleavage

Christopher T Turner,Matthew R Zeglinski,Katlyn C Richardson,Stephanie Santacruz,Sho Hiroyasu,Christine Wang,Hongyan Zhao,Yue Shen,Roma Sehmi,Hermenio Lima,Gail M Gauvreau,David J Granville,Christopher T. Turner,Matthew R. Zeglinski,Katlyn C. Richardson,Gail M. Gauvreau,David J. Granville

DOI: https://doi.org/10.1016/j.jid.2020.05.095

IF: 7.59

2021-01-01

Journal of Investigative Dermatology

Abstract:Atopic dermatitis (AD) is the most common inflammatory skin condition. Skin barrier dysfunction is of major importance in AD as it facilitates allergen sensitization and systemic allergic responses. Long regarded as a pro-apoptotic protease, emerging studies indicate granzyme B (GzmB) to have extracellular roles involving the proteolytic cleavage of extracellular matrix, cell adhesion- and basement membrane -proteins. Minimally expressed in normal skin, GzmB is elevated in AD and positively correlated with disease severity and pruritus. We hypothesized that GzmB contributes to AD through extracellular protein cleavage. A causative role for GzmB was assessed in an oxazolone-induced murine model of dermatitis, comparing GzmB-/- to wild-type mice, showing significant reductions in inflammation, epidermal thickness and lesion formation in GzmB-/- mice. Topical administration of a small molecule GzmB inhibitor reduced disease severity compared to vehicle-treated controls. Mechanistically, GzmB impaired epithelial barrier function through E-cadherin and filaggrin cleavage. Together, GzmB proteolytic activity contributes to impaired epidermal barrier function and represents a valid therapeutic target for AD.

dermatology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the contribution of granzyme B (Granzyme B, GzmB) to barrier dysfunction through the cleavage of E - cadherin and filaggrin in oxazolone - induced skin inflammation. Specifically, the researchers hypothesized that GzmB affects skin barrier function through its proteolytic activity, thereby exacerbating the symptoms of atopic dermatitis (Atopic Dermatitis, AD). To test this hypothesis, the researchers used GzmB - knockout mice (GzmB - / -) and wild - type mice (Wild - Type, WT) for comparative experiments and evaluated the effect of GzmB inhibitors on AD symptoms.

### Research Background
- **Atopic Dermatitis (AD)**: It is the most common inflammatory skin disease. Skin barrier dysfunction plays an important role in AD because it promotes allergen sensitization and systemic allergic reactions.
- **Granzyme B (GzmB)**: Traditionally considered as a pro - apoptotic protease, but recent studies have shown that it also has extracellular functions, such as proteolytic cleavage of extracellular matrix, cell - adhesion proteins and basement membrane proteins.

### Main Findings
- **Expression of GzmB in AD**: The expression of GzmB in AD - affected skin is significantly increased and is positively correlated with disease severity and itchiness.
- **Mechanism of Action of GzmB**: Through the cleavage of E - cadherin and filaggrin, GzmB impairs the epidermal barrier function.
- **Animal Model Verification**: In the oxazolone - induced mouse skin inflammation model, GzmB - knockout mice showed reduced inflammation, decreased epidermal thickness and reduced lesion formation.
- **Effect of GzmB Inhibitors**: Topical application of GzmB inhibitors can significantly alleviate AD symptoms, including reducing ear thickness, improving lesion coverage and epidermal thickness.

### Conclusion
GzmB plays an important role in AD through its proteolytic activity, especially by causing skin barrier dysfunction through the cleavage of E - cadherin and filaggrin. Therefore, GzmB is an effective target for the treatment of AD, and its inhibitors may become a new method for the treatment of AD.